- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | Exelixis' blockbuster hopeful beats Bayer drug in pivotal cancer trial, sending stock soaring | ||
| Mo | Otsuka pens $670M pact to point Harbour's preclinical T-cell engager to autoimmune disease | ||
| Mo | Novo's injectable amycretin yet to hit weight-loss plateau, suggesting Zepbound-beating potential | ||
| Mo | Vertex's remaining islet cell therapy reduces dangerously low blood sugar levels in phase 1/2 test | ||
| 20.06. | FDA blocks new clinical trials that ship cells from US to China | ||
| 20.06. | Syncona blames 'challenging' market for shift in biotech investment strategy | ||
| 20.06. | Prothena lays off 63% of employees in fallout from phase 3 amyloidosis drug fail | ||
| 20.06. | Industry 'deeply disappointed' as FDA puts cell and gene therapy chief on administrative leave | ||
| 18.06. | Zealand Pharma's GLP-1/GLP-2 candidate linked to 11.6% weight loss after 28 weeks | ||
| 18.06. | US accused of denying R&D grants for biotechs based on international investor links | ||
| 18.06. | Taxes, tariffs and interest rates hold key to biotech's future amid uncertain outlook: EY | ||
| 18.06. | Scholar Rock's SMA drug helps weight loss patients on Zepbound retain muscle in phase 2 trial | ||
| 18.06. | China's rapid rise creates 'heightened risks' for pharma: PwC | ||
| 17.06. | FDA launches new priority review voucher program for biopharmas that 'align with national priorities' | ||
| 17.06. | Immuneering sees 94% survival at 6 months in pancreatic cancer, teeing up pivotal trial plans | ||
| 17.06. | Aptose CEO props up biotech's finances to prevent company from going bust | ||
| 17.06. | Mineralys' hypertension drug continues winning streak, lowering blood pressure in phase 2 | ||
| 17.06. | Ventyx posts phase 2 Parkinson's data ahead of potential talks with Sanofi | ||
| 17.06. | Eli Lilly in talks over $1.3B deal for gene editing partner Verve Therapeutics: FT | ||
| 16.06. | Gilead lays off 36 people after axing California expansion plan | ||
| 16.06. | NextCure advances ADC pivot with $745M deal for Simcere's phase 1 drug | ||
| 16.06. | South Korean biotech's GLP-1 drug scores MASH win while reducing weight | ||
| 16.06. | Eli Lilly's phase 1 amylin data impress analysts, pairing 11% weight loss with tolerable profile | ||
| 16.06. | FDA's 'heavy workload' blamed for delays to KalVista's angioedema drug approval decision | ||
| 13.06. | J&J ties early-stage lymphoma CAR-T to 100% response rate in 10 patients |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .